Establishment of Automated Point-of-Care Manufacturing of ΔNPM1 TCR-Engineered T Cells for AML Therapy

被引：0
|
作者：
Ogusuku, Isabella Elias Yonezawa [1 ]
Agiro, Eva [2 ]
Herbel, Vera [1 ]
Brandes, Caroline [1 ]
Veld, Sabrina [2 ]
Hageman, Lois [2 ]
Griffioen, Marieke [2 ]
Schaser, Thomas [1 ]
de Groot, Rosa [2 ]
Lock, Dominik [1 ]
Johnston, Ian C. D. [1 ]
机构：
[1] Miltenyi Biotec BV & Co KG, Bergisch Gladbach, Germany
[2] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
286
引用
收藏
页码：153 / 154
页数：2
相关论文
共 38 条
  • [1] Automated manufacture of A NPM1 TCR-engineered T cells for AML therapy
    Ogusuku, Isabella Elias Yonezawa
    Herbel, Vera
    Lennartz, Simon
    Brandes, Caroline
    Argiro, Eva
    Fabian, Caroline
    Hauck, Carola
    Hoogstraten, Conny
    Veld, Sabrina
    Hageman, Lois
    Teppert, Karin
    Koutsoumpli, Georgia
    Mockel-Tenbrinck, Nadine
    Schaser, Thomas
    de Groot, Rosa
    Johnston, Ian C. D.
    Lock, Dominik
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32
  • [2] Automated Manufacture of dNPM1 TCR-Engineered T Cells for Therapy
    Ogusuku, Isabella Elias Yonezawa
    Herbel, Vera
    Lennartz, Simon
    Fabian, Caroline
    Brandes, Caroline
    Teppert, Karin
    Barth, Carola
    Veld, Sabrina
    Hageman, Lois
    Hoogstraten, Conny
    Koutsoumpli, Georgia
    Griffioen, Marieke
    Schaser, Thomas
    de Groot, Rosa
    Johnston, Ian
    Lock, Dominik
    MOLECULAR THERAPY, 2023, 31 (04) : 546 - 546
  • [3] Automated, closed, GMP-compliant manufacture of TCR-engineered T cells for therapy
    Ogusuku, I. Elias Yonezawa
    Lennartz, S.
    Brandes, C.
    Herbel, V.
    Teppert, K.
    Schaser, T.
    Koutsoumpli, G.
    Griffioen, G.
    Johnston, I.
    Lock, D.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A102 - A102
  • [4] GMP MANUFACTURING OF TCR-ENGINEERED T CELLS IN 5-6 DAYS
    Kalra, M.
    Coughlin, Z.
    Alpert, A.
    Alten, L.
    Bunk, S.
    Wagner, C.
    Fritsche, J.
    Schoor, O.
    Maurer, D.
    Weinschenk, T.
    Sieger, K.
    Mohamed, A.
    Walter, S.
    HUMAN GENE THERAPY, 2019, 30 (12) : A22 - A22
  • [5] Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
    Shafer, Paul
    Kelly, Lauren M.
    Hoyos, Valentina
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] Efficacy of novel combination therapy against AML cells with mutant NPM1
    Mill, Christopher P.
    Fiskus, Warren C.
    Davis, John A.
    DiNardo, Courtney D.
    Birdwell, Christine
    Jin, Qi
    Takahashi, Koichi
    Khoury, Joseph D.
    Bhalla, Kapil N.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML
    van der Lee, Dyantha I.
    Koutsoumpli, Georgia
    Reijmers, Rogier M.
    Honders, M. Willy
    de Jong, Rob C. M.
    Remst, Dennis F. G.
    Wachsmann, Tassilo L. A.
    Hagedoorn, Renate S.
    Franken, Kees L. M. C.
    Kester, Michel G. D.
    Harber, Karl J.
    Roelofsen, Lisanne M.
    Schouten, Annemiek M.
    Mulder, Arend
    Drijfhout, Jan W.
    Veelken, Hendrik
    van Veelen, Peter A.
    Heemskerk, Mirjam H. M.
    Falkenburg, J. H. Frederik
    Griffioen, Marieke
    CANCERS, 2021, 13 (21)
  • [8] Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
    Wachsmann, Tassilo L. A.
    Meeuwsen, Miranda H.
    Remst, Dennis F. G.
    Buchner, Karen
    Wouters, Anne K.
    Hagedoorn, Renate S.
    Falkenburg, J. H. Frederik
    Heemskerk, Mirjam H. M.
    BLOOD ADVANCES, 2023, 7 (20) : 6178 - 6183
  • [9] Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations:: implications for the cell of origin of NPMc plus AML
    Martelli, M. P.
    Manes, N.
    Pettirossi, V.
    Liso, A.
    Pacini, R.
    Mannucci, R.
    Zei, T.
    Bolli, N.
    di Raimondo, F.
    Specchia, G.
    Nicoletti, I.
    Martelli, M. F.
    Falini, B.
    LEUKEMIA, 2008, 22 (01) : 195 - 198
  • [10] Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML
    M P Martelli
    N Manes
    V Pettirossi
    A Liso
    R Pacini
    R Mannucci
    T Zei
    N Bolli
    F di Raimondo
    G Specchia
    I Nicoletti
    M F Martelli
    B Falini
    Leukemia, 2008, 22 : 195 - 198
1234